Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
ddYUPeA2y09Rb8rm